Immunic Stock Jumps After Pricing $400 Million Private Placement

Core Viewpoint - Immunic Inc (NASDAQ:IMUX) is experiencing a significant stock surge following the announcement of a private placement of up to $400 million, indicating strong investor confidence and potential for future growth [1]. Group 1: Financing Details - The financing round was led by existing investor BVF Partners, with participation from notable institutional investors including OrbiMed, RA Capital, Janus Henderson, Avidity Partners, and EcoR1 Capital [2]. - The structure of the deal includes $200 million upfront through pre-funded warrants priced at 87 cents each, with an additional potential $200 million contingent on the exercise of accompanying warrants [3]. Group 2: Use of Funds - The new capital is expected to sustain Immunic through late 2027, primarily funding the completion of Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis, with top-line data anticipated by the end of 2026 [4]. - If the Phase 3 ENSURE trial results are positive, the company plans to file for regulatory approval in mid-2027, targeting a potential green light in 2028 [4]. - Additionally, the financing will enable Immunic to initiate a Phase 3 program in primary progressive multiple sclerosis (PPMS) later this year, with the study projected to last approximately three and a half to four years [5]. Group 3: Stock Performance - Following the announcement, Immunic shares rose by 26.43%, reaching a price of $1.10 at the time of publication [5].